News
-
-
-
PRESS RELEASE
THERANEXUS PUBLISHES ITS 2023 FULL-YEAR RESULTS AND PRESENTS ITS PROGRESS REPORT
Theranexus reports 2023 financial results, cash position, progress report, and the arrival of Christine Placet as CFO. Highlights include positive Batten-1 trial results and funding options for future trials -
-
-
-
PRESS RELEASE
Theranexus, Diverchim and Inserm awarded EUR 4.7 million in funding under the "Innovations in biotherapies and biomanufacturing" call for proposals from France 2030 to develop a novel antisense oligonucleotide
Theranexus, Diverchim, and Inserm's ARNA laboratory receive €4.7 million funding from French Government to develop autophagy activation therapy for rare neurological diseases under the PickASO project in collaboration with France 2030 -
-
PRESS RELEASE
Theranexus and BBDF announce final and positive safety and efficacy data in the Phase I/II trial testing Batten-1
Theranexus and BBDF announce positive final results after 18-month Phase I/II trial of Batten-1 in juvenile Batten disease (CLN3) patients, showing stabilization of motor symptoms progression in young adults
-
LaMar’s Donuts Celebrates National Donut Day 2024
-
abrdn U.S. Closed-End Funds Announce Distribution Payment Details
-
abrdn Income Credit Strategies Fund Announces Update and Tentative Closing Date for Acquisition of Assets From First Trust High Income Long/Short Fund
-
Electric Royalties Announces Interest Conversion Under Convertible Credit Facility
-
Pfister Faucets' American Plumber Stories Docuseries Wins Three Telly Awards
-
EQS-Adhoc: Vectron Systems AG: Vectron enters into Business Combination Agreement, resolves 10% capital increase without subscription rights of the shareholders and supports voluntary public acqusition offer
-
CPI PROPERTY GROUP publishes financial results for the first quarter of 2024
-
Leclanché SA: Publishes its Annual Report 2023 and Non-financial ESG Report
-
Spexis receives second extension for the publication of its 2023 annual report until July 31, 2024, releasing its unaudited financial statements and providing an update on its dispute with SPRIM.
-
Molten Ventures Plc: HOL-Holding(s) in Company
-
ACCOR - Description of own share buyback programme
-
ACCOR - Press release following the 2024 general meeting
-
Capital increase through exercise of subscription rights
-
NFL BIOSCIENCES: RESULTS OF THE COMBINED GENERAL MEETING OF MAY 30, 2024
-
Thales has completed the sale of its Ground Transportation Systems business